Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 30;317(1):789.
doi: 10.1007/s00403-025-04288-7.

Higher incidence of dermatological immune-related adverse events in cancer patients treated with immune checkpoint inhibitors vs. other treatments: a TriNetX research network study

Rahib K Islam  1 , Ryan Chan  2 , Andrew Gross  3 , Hassan Malik  1 , Humza Pirzadah  1 , Ahmed Abdelmaksoud  4   5 , Christopher Haas  6 , Manal Fawzy  7   8 , Eman Toraih  4   9 , Shari R Lipner  10
Affiliations

Higher incidence of dermatological immune-related adverse events in cancer patients treated with immune checkpoint inhibitors vs. other treatments: a TriNetX research network study

Rahib K Islam et al. Arch Dermatol Res. .
No abstract available

Keywords: Cancer treatment; Dermatological adverse events; Immune checkpoint inhibitors; Immune-related adverse events (irAEs); Oncology dermatology; Rash; Stevens-johnson syndrome; Vitiligo.

PubMed Disclaimer

Conflict of interest statement

Declarations. IRB approval status: Not applicable. Financial disclosures: Dr. Lipner has received research funding from Moberg Pharmaceuticals and BelleTorus Corporation. Competing interests: The authors declare no competing interests.

References

    1. Parikh RB, Min EJ, Wileyto EP, Riaz F, Gross CP, Cohen RB, Hubbard RA, Long Q, Mamtani R (2021) Uptake and survival outcomes following immune checkpoint inhibitor therapy among Trial-Ineligible patients with advanced solid cancers. JAMA Oncol 7(12):1843–1850. https://doi.org/10.1001/jamaoncol.2021.4971 - DOI - PubMed
    1. Apalla Z, Rapoport B, Sibaud V (2021) Dermatologic immune-related adverse events: the toxicity spectrum and recommendations for management. International J women’s dermatology 7(5Part A 625–635. https://doi.org/10.1016/j.ijwd.2021.10.005
    1. Wongvibulsin S, Pahalyants V, Kalinich M et al (2022) Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A united States population-level analysis. J Am Acad Dermatol 86(3):563–572. https://doi.org/10.1016/j.jaad.2021.03.094 - DOI - PubMed
    1. Zhang S, Tang K, Wan G et al (2023) Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study. J Am Acad Dermatol 88(5):1024–1032. https://doi.org/10.1016/j.jaad.2022.12.048 - DOI - PubMed - PMC
    1. Curkovic NB, Bai K, Ye F, Johnson DB (2024) Incidence of cutaneous immune-Related adverse events and outcomes in immune checkpoint Inhibitor-Containing regimens: A systematic review and Meta-Analysis. Cancers 16(2):340. https://doi.org/10.3390/cancers16020340 - DOI - PubMed - PMC

LinkOut - more resources